Anders Neil, Ph.D. has been appointed principal consultant at PAREXEL’s European Product Development Practice. Dr. Neil, previously senior expert, Pharmacology and Toxicology, at Sweden’s Medical Products Agency (MPA), will advise clients on all aspects of clinical development and regulatory affairs.

Dr. Neil has more than 20 years of experience in pharmacology research, drug discovery, and drug development. Prior to MPA, Dr. Neil spent more than 10 years in the pharmaceutical industry serving as principal scientist at Biovitrum AB and as group manager, Pharmacology at Kabi-Pharmacia/Pharmacia & Upjohn.

“We expect clients will benefit greatly from the insight Dr. Neil has gained from helping to shape regulatory policies in Europe,” said Peter Lassoff, Pharm.D., vice president, Europe, PAREXEL Consulting. “Dr. Neil’s scientific advice and extensive regulatory and clinical experience will be invaluable in many areas, including in understanding new pediatric requirements as well as applying proactive safety strategies and risk management methodologies. He also brings a wealth of expertise in regard to product development in Sweden, which is the fourth largest biopharmaceutical market in Europe, to supplement our industry leading capabilities in Scandinavia.”

“PAREXEL’s consulting experts are recognized for managing successful interactions with regulatory agencies, delivering world-class submissions, and helping biopharmaceutical companies define and execute the most efficient paths to approval,” said Dr. Neil. “I am proud to join such a high caliber team of experts to help clients with scientific decisions, especially early in development planning, and with regulatory approaches to achieve first-cycle approval.”